SEARCHCROSS-SECTIONALendocrinology, neurology

cross-sectional·endocrinology, neurology, epidemiology, internal medicine·PMC10270586

The association between hyperlipidemia, lipid-lowering drugs and diabetic peripheral neuropathy in patients with type 2 diabetes mellitus

PLOS ONE · 9 authors, 7 centres

AI SUMMARY

FIDELITY 100%

POPULATION2,448 Taiwanese adults with type 2 diabetes mellitus

INTERVENTION

COMPARISONPatients with DPN vs. without DPN; hyperlipidemic vs. normolipidemic; lipid-lowering therapy users vs. non-users

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

This cross-sectional study of 2,448 Taiwanese adults with type 2 diabetes found that neither hyperlipidemia nor lipid-lowering therapy was significantly associated with diabetic peripheral neuropathy. Patients with DPN actually had lower total cholesterol and LDL-C levels than those without DPN.

Full summary

900 CHARS

This cross-sectional, hospital-based study enrolled 2,448 Taiwanese adults with type 2 diabetes from January to October 2013. DPN was screened using the Michigan Neuropathy Screening Instrument (MNSI). Participants with DPN (n=524, 21.4%) had significantly lower total cholesterol (185.6 vs. 193.4 mg/dL) and LDL-C (114.6 vs. Multivariate analysis showed no significant association between hyperlipidemia (aOR 0.81, 95% CI 0.49–1.34) or lipid-lowering therapy (aOR 1.10, 95% CI 0.58–2.09) and DPN. Subgroup analyses for hyper-TC, hyper-LDL-C, statin use, and fibrate use also showed no significant associations. Limitations include reliance on MNSI without nerve conduction studies, cross-sectional design precluding causal inference, ethnic homogeneity of the sample, and exclusion of newer lipid-lowering agents. The findings suggest lipid metabolism may play only a minor role in DPN pathogenesis.

PICO

PPOPULATION

2,448 Taiwanese adults with type 2 diabetes mellitus

OOUTCOME

Diabetic peripheral neuropathy screened using the Michigan Neuropathy Screening Instrument

STUDY TYPE

cross-sectional

SPECIALTY

endocrinology

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10270586

The association between hyperlipidemia, lipid-lowering drugs and diabetic peripheral neuropathy in patients with type 2 diabetes mellitus

PLOS ONE

READ THE FULL PAPER

ABSTRACT

Abstract Aims Previous studies showed conflicting relationship between hyperlipidemia, lipid-lowering therapy and diabetic peripheral neuropathy (DPN). As most of these works emerges from the Western and Australian countries, our study aims to investigate whether hyperlipidemia or lipid-lowering therapy (LLT) is associated with DPN in Taiwanese patients with type 2 diabetes (T2D). Methods A cross-sectional, hospital-based observation study in adults with T2D was conducted from January to October 2013. DPN was screened using the Michigan Neuropathy Screening Instrument. Data were obtained at the time of enrollment, including medication usage, anthropometric measurements and laboratory examinations. Results 2,448 participants were enrolled, 524 (21.4%) of whom had DPN. Patients with DPN had significantly lower plasma total cholesterol (185.6 ± 38.6 vs 193.4 ± 42.3 mg/dL) and low-density lipoprotein cholesterol levels (114.6 ± 32.7 vs 119 ± 30.8 mg/dL). Multivariate analysis demonstrated that neither hyperlipidemia (adjusted OR (aOR), 0.81; 95% confidence interval (CI), 0.49–1.34) nor LLT (aOR, 1.10; 95% CI, 0.58–2.09) was associated with DPN. Subgroup analysis revealed that neither total cholesterol (aOR, 0.72; 95% CI, 0.2–2.62), low-density lipoprotein cholesterol levels (aOR, 0.75; 95% CI, 0.2–2.79), statin (aOR, 1.09; 95% CI, 0.59–2.03) nor fibrate (aOR, 1.73; 95% CI, 0.33–1.61) was associated with DPN. Conclusion Our results suggest that neither hyperlipidemia nor lipid-lowering medication was associated with DPN in adults with T2D. DPN is a multifactorial disease, and our findings indicate that lipid metabolism may play a minor role in its pathogenesis.

CITATION EXPORT

Kuo-Cheng Chang, Yen-Wei Pai, Ching-Heng Lin et al.. The association between hyperlipidemia, lipid-lowering drugs and diabetic peripheral neuropathy in patients with type 2 diabetes mellitus. PLOS ONE. (2023). https://doi.org/10.1371/journal.pone.0287373

AUTHORS

9 · 7 CENTRES

Kuo-Cheng Chang, Yen-Wei Pai, Ching-Heng Lin, I-Te Lee, Ming-Hong Chang, Alok Raghav, Hanna Landenmark, Fredirick Lazaro mashili, Fredirick Lazaro mashili

1Neurological Institute, Taichung Veterans General Hospital, Taichung, Taiwan
2Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan
3Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan
4Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
5Department of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan
6Department of Medicine, School of Medicine, Chung Shan Medical University, Taichung, Taiwan
7Muhimbili University of Health and Allied Sciences School of Medicine, UNITED REPUBLIC OF TANZANIA